Nan C, et al. - In order to assess the association between abacavir (ABC) use and myocardial infarction (MI), researchers performed a pooled analysis of 66 Phase II–IV randomized controlled trials (RCTs) and estimated exposure-adjusted incidence rates (IRs) and relative rates (RRs) of MI and cardiovascular events (CVEs) in participants receiving ABC- and non–ABC-containing combination antiretroviral therapy (cART). Findings revealed comparable IRs for MI and CVEs among ABC-exposed and unexposed participants. Hence, ABC exposure in a clinical trial population appeared not increasing the risk for MI or CVEs. They recommended addressing modifiable risk factors for MI and CVEs when prescribing ART.